News Image

BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant

Provided By GlobeNewswire

Last update: Apr 10, 2025

Monrovia, CA, April 10, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced its latest initiative - BioClick - a pioneering concept designed to enhance and accelerate the engineering of enzymes for advanced chemical reactions. Funded in part by a $300K grant from the National Institutes of Health (NIH), this project has the potential to revolutionize how medicines and other bio-based compounds are created.

Read more at globenewswire.com

EXOZYMES INC

NASDAQ:EXOZ (4/23/2025, 8:02:11 PM)

13.53

+1.74 (+14.76%)



Find more stocks in the Stock Screener

Follow ChartMill for more